The Huangfu laboratory is interested in understanding human biology through the lens of human pluripotent stem cells (hPSCs), including embryonic and induced pluripotent stem cells (hESCs and hiPSCs). Our specific goal is to understand how insulin-secreting β cells form and function in the context of normal development, adult tissue maintenance and regeneration, aging, and disease. The pathways that regulate these processes can be exploited for therapeutics to prevent and reverse diseases such as type 1 and type 2 diabetes.
Danwei Huangfu, PhD
Research FocusDevelopmental biologist Danwei Huangfu uses human pluripotent stem cells (hPSCs) as a powerful genetic model to interrogate the transcriptional and epigenetic mechanisms underlying cell fate decisions in development and disease.
EducationPhD, Weill Cornell Graduate School of Medical Sciences
- Genome-scale screens identify JNK-JUN signaling as a barrier for pluripotency exit and endoderm differentiation. Li QV, Dixon G, Verma N, Rosen BP, Gordillo M, Luo R, Xu C, Wang Q, Soh CL, Yang D, Crespo M, Shukla A, Xiang Q, Dündar F, Zumbo P, Witkin M, Koche R, Betel D, Chen S, Massagué J, Garippa R, Evans T, Beer MA, Huangfu D. Nat Genet. 2019 Jun;51(6):999-1010.
- TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang CJ, Papapetrou EP, He C, Elemento O, Huangfu D. Nat Genet. 2018 Jan;50(1):83-95.
- Basil O’Connor Scholar, March of Dimes Birth Defects Foundation (2012-2014)
- Louis V. Gerstner, Jr. Young Investigators Award, Memorial Sloan Kettering Cancer Center (2011-2014)
- Award from Harvard Catalyst & InnoCentive for the Ideation Challenge on “What Do We Not Know to Cure Type 1 Diabetes” (2010)
- Helen Hay Whitney Postdoctoral Fellowship (2006-2009)